Related Experiment Videos
[Acute pharyngo-tonsillitis. Penicillin, yes or no?]
F Sanabria Gómez1, C Cenjor Español, F Márquez Dorsch
1Servicio de Otorrinolaringología, Fundación Jiménez Díaz, Madrid.
Abstract:
Acute tonsillitis and acute pharyngitis show a high incidence in the healthy population. Recent microbiological studies have demonstrated changes in the frequency with which different microorganisms promote such infections. This fac, together with the variations in sensibility or resistance of germs to the diverse therapeutic agents, have led to the conclusion that penicillin must not be considered as the solo drug of choice in these infections.
Insights
Penicillin is no longer the sole treatment for acute tonsillitis and pharyngitis. Evolving germ resistance necessitates exploring alternative therapeutic agents for these common infections.
Area of Science:
- Infectious Diseases
- Microbiology
- Pharmacology
Context:
- Acute tonsillitis and acute pharyngitis are common infections in the general population.
- Recent microbiological data reveal shifts in causative microorganisms.
- Variations in microbial susceptibility to antibiotics are increasingly observed.
Purpose:
- To evaluate the current landscape of causative agents in acute tonsillitis and pharyngitis.
- To assess the impact of changing microbial resistance patterns on treatment efficacy.
- To challenge the long-standing reliance on penicillin as the primary therapeutic agent.
Summary:
- Microbiological studies indicate evolving patterns in the microorganisms responsible for acute tonsillitis and pharyngitis.
- Observed variations in bacterial sensitivity and resistance to antimicrobial drugs are significant.
- These findings suggest that penicillin should not be considered the exclusive treatment option.
Impact:
- Highlights the need for updated treatment guidelines for acute tonsillitis and pharyngitis.
- Emphasizes the importance of considering antibiotic resistance in clinical decision-making.
- Supports the exploration and utilization of alternative antimicrobial therapies.